VIDEO: Don’t leave PKI analysis behind in lung cancer immunotherapy – Healio

Source/Disclosures

Source:

Healio Interview

Disclosures:
Stevenson reports receiving clinical trial research funding from Bristol-Meyers Squibb and Merck.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

ADDED TO EMAIL ALERTS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

In this video, James Stevenson, MD, a medical oncologist and hematologist at Cleveland Clinic, highlighted findings from the PIONeeR trial, which was presented at ESMO Virtual Congress 2020.

“Pharmacokinetics is worthy of a bit more study in immunotherapies because …some of [us] think that pharmacokinetics might not matter as much as they do with chemo-therapeutics,” Stevenson said. “But it may turn out that PKI analyses are important for immunotherapies as well.”

References:

• Barlesi F, et al. Abstract LBA53. Presented at: European Society for Medical Oncology Virtual Congress 2020; Sept. 19-21, 2020.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

ADDED TO EMAIL ALERTS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Take Homes in Lung Cancer

Published at Tue, 06 Oct 2020 15:01:34 +0000